Updated:
WBB Securities
WBB Securities is a leading Investment Management, Investment Banking, and Equity Research firm focused primarily on the life sciences niche.
WBB Securities
WBB Securities is a leading Investment Management, Investment Banking, and Equity Research firm focused primarily on the life sciences niche. Established in 2001 with offices in New Jersey, New York, and California, it as a broker-dealer, a member of FINRA, and a state-registered investment adviser with a proprietary trading desk. The firm has a nationwide team of senior investment and research professionals serving institutional and high-net-worth clients, and its investment bank has participated in over 250 transactions leading to $4 billion placed.
General information
Firm type
Asset Manager
Year founded
1992
Location
Region
North America
Country
United States
City
Cranford
Corporate office
Piscataway, NJ, United States
Principals
Derek T. Youngblood
President, CEO
Peter H. Imhof
Executive Vice President, Head of Investment Banking
Sector focus
Frequently asked questions
Who runs investment decisions at WBB Securities?
Derek T. Youngblood serves as President and CEO. Peter H. Imhof is the Executive Vice President and Head of Investment Banking. The firm's research and trading functions are managed by senior professionals, though specific role titles are not all publicly disclosed.
What investment stages does WBB Securities typically target?
The firm focuses on small- and micro-cap public companies, often in the life sciences and healthcare sectors. It provides capital raising through follow-on offerings, private placements, and PIPEs, and also advises on strategic transactions such as mergers and acquisitions.
Which sectors does WBB Securities focus on?
The firm concentrates on life sciences, biotechnology, and healthcare services. It also has some coverage in enterprise software and financial technology, especially when these intersect with healthcare or life sciences.
How does WBB Securities source proprietary deal flow?
The firm generates deal flow through its in-house equity research coverage, which provides differentiated insights on small-cap life sciences companies. This research drives institutional interest and leads to advisory mandates for financings and strategic transactions.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on registered investment advisers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: